A cellular genetics approach identifies gene-drug interactions and pinpoints drug toxicity pathway nodes by Oscar T. Suzuki et al.
ORIGINAL RESEARCH ARTICLE
published: 29 August 2014
doi: 10.3389/fgene.2014.00272
A cellular genetics approach identifies gene-drug
interactions and pinpoints drug toxicity pathway nodes
Oscar T. Suzuki1, Amber Frick1, Bethany B. Parks2, O. Joseph Trask Jr.2, Natasha Butz1†,
Brian Steffy1†, Emmanuel Chan1, David K. Scoville1†, Eric Healy2, Cristina Benton1,
Patricia E. McQuaid3, Russell S. Thomas2† and Tim Wiltshire1*
1 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill, Chapel Hill,
NC, USA
2 The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA
3 Meredith College, Raleigh, NC, USA
Edited by:
Nora L. Nock, Case Western
Reserve University, USA
Reviewed by:
Lei Lu, University of Chicago
Medical Center, USA
Natalie C. Fonville, Virginia Tech,
USA
Ping Gong, US Army Engineer
Research and Development Center,
USA
*Correspondence:
Tim Wiltshire, Eshelman School of
Pharmacy, University of North
Carolina, Genetic Medicine Building
Rm. 1015, 120 Mason Farm Road,
CB 7361, Chapel Hill,
NC 27599-7361, USA
e-mail: timw@unc.edu
†Present address:
Natasha Butz, Center for
Gastrointestinal Biology and
Diseases, School of Medicine,
University of North Carolina,
Chapel Hill, USA;
Brian Steffy, Illumina, Inc. San
Diego, USA;
David K. Scoville, Department of
Environmental and Occupational
Health Sciences, University of
Washington, Seattle, USA;
Russell S. Thomas, U.S.
Environmental Protection Agency,
Research Triangle Park, USA
New approaches to toxicity testing have incorporated high-throughput screening across a
broad-range of in vitro assays to identify potential key events in response to chemical
or drug treatment. To date, these approaches have primarily utilized repurposed drug
discovery assays. In this study, we describe an approach that combines in vitro screening
with genetic approaches for the experimental identification of genes and pathways
involved in chemical or drug toxicity. Primary embryonic fibroblasts isolated from 32
genetically-characterized inbred mouse strains were treated in concentration-response
format with 65 compounds, including pharmaceutical drugs, environmental chemicals, and
compounds with known modes-of-action. Integrated cellular responses were measured at
24 and 72 h using high-content imaging and included cell loss, membrane permeability,
mitochondrial function, and apoptosis. Genetic association analysis of cross-strain
differences in the cellular responses resulted in a collection of candidate loci potentially
underlying the variable strain response to each chemical. As a demonstration of the
approach, one candidate gene involved in rotenone sensitivity, Cybb, was experimentally
validated in vitro and in vivo. Pathway analysis on the combined list of candidate loci
across all chemicals identified a number of over-connected nodes that may serve as core
regulatory points in toxicity pathways.
Keywords: high throughput screening, mouse model, in vitro screening, high-content imaging, gene-drug
interaction, genome-wide association
INTRODUCTION
Toxicology and toxicity testing are in the midst of a transforma-
tion. A series of expert panels, workshops, and strategic reviews
have proposed a transition from an apical endpoint-based eval-
uation of chemical and drug safety to a focus on identifying
key molecular initiating events and pathway perturbations lead-
ing to adverse effects (Woodruff et al., 2008; Firestone et al.,
2010; Berg et al., 2011; Silbergeld et al., 2011; Keller et al.,
2012). The proposed transition is being driven by the need to
reduce the cost and time associated with evaluating the safety
of drugs and chemicals, to allow broader coverage of com-
pounds, mixtures, endpoints and life-stages in the evaluation,
and to provide a more robust basis for risk assessment through
the identification and application of mechanistic data (National
Research Council. Committee on Toxicity Testing and Assessment
of Environmental Agents, 2007). Within the National Research
Council (NRC) report, the initiating event and subsequent path-
way perturbation were collapsed into the term, toxicity pathway,
and this term was explicitly defined as “cellular response path-
ways that, when sufficiently perturbed, are expected to result in
adverse health effects” (National Research Council. Committee
on Toxicity Testing and Assessment of Environmental Agents,
2007).
The sequencing of multiple mammalian genomes, includ-
ing both mouse (Waterston et al., 2002) and human (Venter
et al., 2001), has led to a series of new approaches using
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genetics to identify the mode-of-action leading to adverse effects
of certain drug or chemical exposures. In particular, inbred
mouse strains provide a unique resource for toxicogenetic
studies. They have extensive, publicly-available genotype data,
enabling genome-wide association analysis on phenotypic dif-
ferences identified following drug or chemical treatment. In an
example of the application of inbred mouse strains to eval-
uate mode-of-action, Harrill and colleagues demonstrated an
association between a variant of the orthologous human gene,
CD44, and acetaminophen hepatotoxicity (Harrill et al., 2009).
Genetic approaches to chemical and drug toxicity have also been
applied in vitro using lymphoblastoid cell lines from the Centre
d’Etude du Polymorphisme Humain (CEPH) panel (Peters et al.,
2009; O’Shea et al., 2011; Watson et al., 2011a,b; Lock et al.,
2012).
In the present study, we described the development and
application of a complementary high-throughput cellular genet-
ics platform to experimentally identify genetic determinants of
chemical toxicity and define potential core nodes in toxicity
pathways. Primary mouse embryonic fibroblasts (MEFs) from
32 inbred mouse strains were treated in concentration-response
format with 65 diverse environmental and pharmaceutical com-
pounds. Phenotypic parameters of cell health status were mea-
sured using high-content imaging and genetic association analysis
of cross-strain differences in the cellular responses was used to
identify candidate genes underlying such differences. The results
of the study suggest that the screening approach can identify
genes involved in the cytotoxic response to each chemical and
that pathway analysis on the combined list of candidate genes
across all chemicals may identify common toxicological response
regulatory nodes.
MATERIALS AND METHODS
COMPOUNDS
A total of 65 compounds were evaluated—26 were ToxCast Phase
I compounds, 27 were pharmaceutical compounds, and 12 were
mechanistic compounds with known modes-of-action (Data
Sheet 1). The ToxCast compounds were chosen based on early
cytotoxicity screening results from the ToxCast program as well as
a diversity in in vivo adverse responses for comparative data analy-
ses. The pharmaceutical compounds were chosen to include drugs
known to be involved in a range of adverse reactions (e.g., drug-
induced liver injury) and those generally considered safe (e.g.,
aspirin and ibuprofen), for a comprehensive assessment of cellu-
lar toxicity profiles. The mechanistic compounds were chosen to
provide a core set of putative cellular toxicity pathways. Each com-
pound was screened at nine concentrations that ranged from 15
to 100 uM, facilitating concentration-response analyses. All com-
pound stock solutions and subsequent dilutions were prepared
in DMSO, with the exception of ibuprofen, which was diluted in
water. Master 384-well microplates were prepared for each com-
pound using the layout provided in Presentation 1. Three-fold
compound serial dilutions were prepared using a Biomek 2000
(Beckman Coulter, Brea, CA), and the final concentration ranges
are listed in Data Sheet 1. A separate microplate was prepared
with 8.33mM of valinomycin solution for positive control wells;
final concentration was 33μM.
CELL CULTURE
Primary MEF cells from 32 inbred mouse strains were purchased
as custom isolations (P0 cultures combined from multiple 12.5
day-old embryos) from The Jackson Laboratory (Bar Harbor,
ME). A minimum of 6 embryos were used for each strain. The
selected inbred mouse strains were a subset of strains from the
Mouse Phenome Panel (Bogue and Grubb, 2004) and included
the 129S1/SvImJ, A/J, AKR/J, BALB/cByJ, BTBR T+ tf /J (cur-
rently named BTBR T+ Itpr3tf /J), BUB/BnJ, C3H/HeJ, C57BL/6J,
C57BR/cdJ, C57L/J, CBA/J, CE/J, CZECHII/EiJ, DBA/2J, FVB/NJ,
I/LnJ, KK/HlJ, LG/J, LP/J, MRL/MpJ, NOD/LtJ, NON/LtJ,
NOR/LtJ, NZO/HlLtJ, NZW/LacJ, PL/J, RIIIS/J, SEA/GnJ, SJL/J,
SM/J, SWR/J, and WSB/EiJ strains of mice. Prior to use in
the study, MEFs from each strain were expanded from P0 to
P3, frozen in cryotubes containing 10% DMSO (Sigma-Aldrich,
Milwaukee, WI), and stored in liquid nitrogen.
To prepare for screening, the MEFs from each strain
were thawed and cultured in tissue-culture-treated, filter cap
CELLSTAR flasks (Greiner Bio-One, Monroe, NC) using modi-
fied DMEM growth media, (Cellgro, Manassas, VA) containing
10% v/v fetal bovine serum (Cellgro, Manassas, VA), 1% v/v non-
essential amino acid solution, (Sigma-Aldrich, Milwaukee, WI),
and 1% v/v penicillin/streptomycin solution (Sigma-Aldrich,
Milwaukee, WI). The cells were maintained in a humidified
environment at 37◦C and 5% CO2. Due to some strain vari-
ation in growth rates, the thawing and plating of the MEF
cells was staggered to achieve ∼90% density at the time of
screening.
HIGH CONTENT SCREENING
On the day of plating, MEF cells were washed with phosphate-
buffered saline (PBS, Gibco-Life Technologies, Grand Island,
NY), trypsinized (1X Trypsin-EDTA solution, Sigma-Aldrich,
Milwaukee, WI), harvested, and the concentration of the cell
suspension was determined using an Invitrogen Countess auto-
mated cell counter (Invitrogen, Carlsbad, CA). The cells were
diluted in complete media to a concentration of 5 × 104 cells/ml
and then seeded into 384-well, PDL-coated microplates using
Multidrop 384 dispensers (Thermo Scientific, Waltham, MA).
Every microplate contained 12 wells for each of the 32 strains
(Presentation 1). Two different microplates were used in the
screening protocol (Perkin Elmer View plates, PDL-coated, Cat #.
6007718; Aurora 200μM film bottom with COP polymer; Cat #.
32411). Cells were plated at two different densities: 1500 cells/well
for plates assigned to the 24 h time point and 1000 cells/well for
the 72 h time point. For both time points the final volume of
cell culture media per well was 50μl. The plates were incubated
overnight at 37◦C and 5% CO2 to allow for cell attachment.
The cells were treated with compound following the incuba-
tion period by transfer of 200 nl of compound stock solution from
the master 384-well microplates using a pin tool (VP 384FP1CB
Pin tool with FP3NS200H pins, V&P Scientific, San Diego, CA)
and a Biomek FX system (Beckman Coulter, Brea, CA). Triplicate
plates were treated for each compound and time point. Among
the 12 wells for each MEF cell line on each plate, 9 wells were
used for the concentration response of the compound of inter-
est (15–100 uM); one well was treated with an equivalent volume
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of vehicle (DMSO or water); one well was treated with a posi-
tive reference compound (33μM); and one well did not receive
any treatment (Figure 1A). For the compounds where DMSOwas
used as vehicle, the final concentration of DMSO was 0.4%.
After 24 or 72 h of treatment, cells were labeled and pro-
cessed using a modified Cellomics Multiparameter Cytotoxicity 3
Kit (Thermo Scientific, Rockford, IL). The protocol was adapted
from a 96-well plate assay to a 384-well plate assay. The kit
contained Hoechst 33342 nucleic acid dye, a cell and nuclei
permeability dye, a mitochondrial membrane potential dye,
a primary monoclonal cytochrome c antibody matched with
secondary DyLight-649 conjugated goat anti-mouse IgG anti-
body, wash buffers, permeabilization buffer, and blocking buffer.
Briefly, 13μl/well of Live Cell Staining Solution (containingmito-
chondrial membrane potential dye and cell permeability dye)
was added to each well and the cells were incubated at 37◦C
for 30min. The cells were then fixed with 21μl/well of 16%
paraformaldehyde for 20min at room temperature. Following fix-
ation, the solution was removed and the cells were washed with
50μl/well wash buffer. The cells were then permeabilized with
25μl/well permeabilization buffer for 10min at room temper-
ature. The cells were washed twice with 50μl/well wash buffer.
The cells were blocked with 25μl/well blocking buffer for 15min
at room temperature. The blocking buffer was removed and
13μl/well of the primary antibody solution was added. The
cells were incubated for 60min at room temperature. The cells
were washed three times with 50μl/well wash buffer and then
incubated for 60min with 13μl/well of the secondary antibody
solution. The cells were washed again three times with 50μl/well
wash buffer. An additional 50μl/well of wash buffer was added
to the cells and sealed for scanning. All washing steps were per-
formed using a BioTek ELx405 Select Microplate Washer (BioTek,
Winooski, VT).
Plates were delivered to a BD Pathway 435 high-content imag-
ing instrument (BD Biosciences, Franklin Lakes, NJ) equipped
with 200W metal halide lamp (89 North, Burlington, VT), using
a Twister II plate handling robot (Perkin Elmer, Hopkinton, MA).
Accurate focusing and acquisition of cell images was accom-
plished using laser-based auto-focusing. Excitation (ex), dichroic
mirror (dm), and emission (em) wavelengths are expressed in
nanometers units, and approximate exposure value (ev) times to
achieve at least 25% signal saturation are expressed as seconds for
the following probes: Hoechst 33342 (ex 377/dm 409/em 435/ev
0.014); cell permeability dye (ex 482/dm 506/em 536/ev 0.008);
mitochondria potential probe (ex 543/dm 562/em 593/ev 0.012);
and cytochrome c—DL649 (ex 628/dm 660/em 692/ev 0.25). A
pixel array size of 2784 × 1536 from a 4 × 3 tile montage of
acquired images were captured using 2× CCD camera binning
through an Olympus 20× / 0.75 NA objective lens (Figure 1B).
All images were saved in BD Attovision software in native file
format (TIF). The images were manually reviewed for quality to
identify: (1) fluorescent artifacts; (2) images that failed to focus;
(3) absence of cell objects in image; and (4) wells with poor algo-
rithmic fit of image. Images showing any of these qualities were
removed from the analysis.
The image files passing the quality check were renamed
using automated Perl script commands to satisfy nomenclature
for using the Thermo Scientific Cellomics vHCS Toolbox
Compartmental Analysis bioapplication algorithm. Camera input
dimensions equal to 2784 × 1536 were programmed into the
vHCS Toolbox for interpretation of all plate well images. The
bioapplication algorithm measurement of pixel size, shape, and
intensity of cell objects from each fluorescent probe in the wells
were calculated based on segmentation and thresholding of indi-
vidual objects. Each cell nuclei of Hoechst 33342 label intensity
was used to identify and collectively enumerate cell objects per
image in the scannable area in the well; doublets and small objects
outside of threshold values were rejected. The primary well level
summary values extracted from the images were the number
of nuclei (cell loss); mean average fluorescence intensity of the
mitochondrial membrane potential dye in the cytoplasm area
(mitochondrial function); mean average fluorescent intensity of
cytochrome c in the cytoplasm (apoptosis); and the mean average
fluorescence intensity of the permeability dye within the nuclear
area (membrane permeability) (Figure 1C).
CONCENTRATION-RESPONSE ANALYSIS AND QUANTITATIVE TRAIT
LOCI (QTL) MAPPING
For each strain, the numerical values generated by the image
analysis bioapplication algorithm were normalized using the
value obtained for the vehicle only well of the respective plate.
Concentration-response curves were generated for each MEF line
by fitting the normalized data in triplicate to the Brain-Cousens
model (Brain and Cousens, 1989). The reason the Brain-Cousens
model was used as opposed to more traditional models (e.g.,
Hill model) was its ability to accommodate both monotonic and
non-monotonic concentration response curves since a significant
number of treatments and MEF lines showed non-monotonic
concentration-response behavior. The fitting was performed
within a custom Java application using the drc package (version
2.0-1; http://www.bioassay.dk) for R (version 2.10.1; http://www.
r-project.org) (Figure 1D). In cases where the curve fitting failed
due to data points that were clearly outliers, they were manu-
ally removed. A maximum of four points were removed from a
single curve (from 27 total points in a curve: nine doses in trip-
licates); the total number of data points removed among the 32
strains for each drug-endpoint pair is presented as Data Sheet 2.
For endpoints showing decreasing response values with increas-
ing concentrations (cell loss and mitochondrial function), the
curves were then used to calculate individual EC50 up through
EC80 values in 6 stepwise increments for each of the strains (i.e.,
EC50,EC55,EC60,EC65,etc.) (Figure 2A). For endpoints showing
increasing response values with increasing concentrations (mem-
brane permeability and apoptosis), EC120 up through EC150 were
calculated in 6 stepwise increments for each strain (Figure 2B).
Genome-wide association (GWA) mapping was performed
for each of the ECn values from each assay endpoint and time
point using the SNPster algorithm (McClurg et al., 2007). This
approach defines genomic loci that associate with the phe-
notype pattern and are termed quantitative trait loci. Values
used in the association analysis can be found in Data Sheet 3.
Compounds were used for genetic analysis only if a minimum
of 25 strains had at least three interpolated ECn values, thus
excluding the compounds with no or minimal observed effect in
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FIGURE 1 | Experimental flow chart for high-content screening of the
MEF lines in concentration-response format across 65 diverse
compounds. (A) MEF cells from 32 inbred strains are plated into a single
384 well plate. Compound is added from a master plate using a 200 nl
pin-tool resulting in 9 concentrations of compound (15 nM to 100μM for
most chemicals, Data Sheet 1 contains the different ranges used), one
positive control compound and two wells of negative control, DMSO
control, and no treatment control. (B) Cell staining reagents are added,
incubated, and then imaged with a high-content imaging system. Image 1:
nuclei staining with Hoechst 33342; image 2: membrane permeability dye
channel; image 3: mitochondrial membrane potential dye; image 4:
cytochrome C antibody staining. (C) Images are analyzed and segmented
using the Cellomics vHCS Toolbox Compartmental Analysis bioapplication.
(D) Dose-response curves generated for each assay endpoint. EC50 to
EC80 or EC120 to EC150 values are generated in 5-point intervals for each
assay per strain.
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FIGURE 2 | Examples of increasing and decreasing concentration
response curves. The concentration response curves for each endpoint
were fit using a Brain-Cousens model and ECn values were interpolated at
defined intervals. (A) For decreasing responses, EC50–EC80 were
calculated in 5% steps. (B) For increasing values, EC120–EC150 were
calculated in 5% steps.
the concentration-response curves. The selected GWA approach
uses the haplotype structure inferred from overlapping 3-SNP
windows. An F-statistic is calculated from the phenotype val-
ues grouped according to the different haplotypes by a One-Way
ANOVA test; p-values are estimated by bootstrapping the phe-
notypic values, 1 × 106 bootstraps were used, giving SNPster a
maximum -log(p-value) score of 6.0 (McClurg et al., 2007). The
SNP genotypes used for SNPster were obtained from the Mouse
Diversity Array set (Yang et al., 2009), which are available from the
CGDSNPdb website (http://cgd.jax.org/cgdsnpdb/). The identifi-
cation of QTLs for each endpoint was done by selecting the top
2% SNPs by -log(p-value) of each ECn and then averaging the -
log(p-value) of all ECn at each SNP position. Genomic regions
with mean -log(p-value) greater than or equal to 3.5, including a
window of 100 kb on each side, were selected for further anal-
ysis. The region between two SNPs with a mean -log(p-value)
above or equal to a threshold of 3.5 was included if the SNPs were
within less than 1Mb of each other. Candidate quantitative trait
genes (QTG) that completely or partially overlap with the regions
associated with drug response were selected for validation or net-
work analysis. To restrict the downstream analyses to genes more
likely to be relevant to the cellular responses in MEFs, only genes
with known expression inMEFs were used. Expression levels were
measured in MEFs from six inbred strains of mice (A/J, AKR/J,
C3H/HeJ, C57BL/6J, CBA/J, DBA/2J) using the AffymetrixMouse
Genome 430 2.0 Array (Affymetrix, Santa Clara, CA). Genes were
considered expressed if the expression level, after data processing
with the gcRMA algorithm, was greater than a value of 50 for at
least one of the strains.
NETWORK ANALYSIS
Due to the relatively small number of candidate genes identified
for each endpoint, the candidate genes were combined for net-
work analysis. A full list of candidate genes and their associated
endpoints are listed in Data Sheet 4. The identification of over-
connected network nodes was conducted using the MetaCore
database (Version 6.12 build 42289, GeneGo, St. Joseph, MI).
The p-values associated with the overconnection analysis were
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calculated based on a hypergeometric distribution. The p-value
is the probability of randomly obtaining the observed size of
intersection between the candidate gene list and the network or
pathway from the MetaCore database. The p-values were cor-
rected for multiple comparisons using false discovery rate (FDR;
Benjamini and Hochberg, 1995).
CANDIDATE GENE IN VITRO VALIDATION
The gene chosen for experimental validation was selected based
on literature evidence of biological relevance, expression level in
MEFs, and correlation between EC values and expression levels
in other tissues (spleen, liver, and adipose tissues). A gene would
only be considered for validation if is expressed in MEFs. In this
manuscript, we present the validation of Cybb as a candidate gene
for variable sensitivity in cell loss following rotenone treatment
using in vitro knockdown and overexpression approaches as an
example to show the utility of the toxicogenetic screen for gene
identification.
C57BL/6J MEFs were electroporated using the Amaxa sys-
tem (MEF1 Nucleofector Kit with the T-20 program; Lonza,
Basel, Switzerland). A total of 2 × 106 cells were used per elec-
troporation. Overexpression was achieved using pCMV-SPORT6
vectors containing the Cybb cDNA (MMM1013-9498866; Open
Biosystems, Lafayette, CO). Cells were co-transfected with 3μg
of Cybb pCMV-SPORT6 and 2μg of pmaxGFP plasmid (Lonza,
Basel, Switzerland). Electroporation efficiency was determined
by flow cytometry to be 40%. Knockdown was performed using
siRNA oligonucleotides (sc-5827; Santa Cruz Biotechnology,
Santa Cruz, CA). An siRNA oligonucleotide that does not specif-
ically target any known cellular mRNA was used as control (sc-
45924; Santa Cruz Biotechnology, Santa Cruz, CA). Transfected
cells were plated in 96-well plates. Eight replicate wells were used
for each rotenone concentration in the overexpression experi-
ment, and three replicates were used in the knockdown exper-
iment. Cells electroporated with the overexpression vector were
incubated for 24 h prior to treatment, and cells transfected with
siRNA oligonucleotides were incubated for 48 h before treatment
to allow for a reduction in the amount of the targeted proteins
in the cells. Cells were treated with rotenone in concentration-
response format from 0.13 to 100μM. Treated cells were, after
24 and 72 h, fixed with 4% paraformaldehyde in PBS and stained
with Hoechst 33342. Fixed cells were imaged with a Cellomics
ArrayScan VTI HCS Reader (Thermo Scientific, Rockford, IL).
A total of 10 fields were captured in each well using a 10X objec-
tive. Images were analyzed using the Cellomics Compartmental
Analysis HCS BioApplication (Thermo Scientific) to determine
the cell number at each concentration.
Transfected cells were also used for mRNA isolation to
confirm the overexpression and knockdown of the genes at
the same time points. Total cell RNA was isolated using the
RNeasy Mini Kit (Qiagen, Hilden, Germany) followed by a
reverse transcription reaction using Superscript II Reverse
Transcriptase (Invitrogen, Carlsbad, CA) and random hex-
amers. Quantitative PCR (qPCR) was performed in duplicate
using SYBR Green (Thermo Scientific, Rockford, IL; forward
primer: ACACTGACCTCTGCTCCTGAG, reverse primer:
TCTTCACTGGCTGTACCAAAG) on a CFX96 real-time
PCR system (Bio-Rad, Hercules, CA). Fold-change in
gene expression was determined using the Ct method
with the B2m gene as an endogenous control (forward
primer: TTCTGGTGCTTGTCTCACTGA, reverse primer:
CAGTATGTTCGGCTTCCCATTC).
CANDIDATE GENE IN VIVO VALIDATION
Based on the haplotypes present in the chromosome X region
associated with rotenone cellular response, two mouse strains
were selected for in vivo validation. FVB/NJ and BTBR T+ tf /J
(SNPster GGA and ATG haplotypes, respectively; Figure 3). All
animal experiments were conducted on approved protocols under
the direction of the UNC Institutional Animal Care and Use
Committee (IACUC). All in vivo experiments were performed
using male mice, 9–10 weeks of age. Animals were subjected to
a treadmill endurance test after repeated exposure to rotenone.
Twelve mice from each strain were obtained from The Jackson
Laboratory (Bar Harbor, ME). Mice were maintained on a 12:12 h
light/dark cycle and given water and food ad lib. Mice received
daily IP injections of vehicle (n = 6) or 0.05mg/kg of rotenone
(Sigma-Aldrich) diluted in olive oil (n = 6) from 0800 to 1200
for 14 days. Body weight was measured and recorded daily from
0800 to 1200 for each mouse. After study treatment, mice were
trained on an Exer-3/6 Open Treadmill apparatus (Columbus
Instruments, Columbus, Ohio) for three consecutive days for 17,
18.5, and 21.5min, respectively. Following training, mice were
tested on Day 4 for endurance at the same time as the training
days (1400–1800). Mice were placed individually on an Exer-3/6
treadmill lane and forced to exercise via an electrical stimulus grid
attached to the treadmill. The final test was conducted on a 5◦
inclination with gradual acceleration from 0 to 8m/min for the
first 120 s. Then, speed was slowly increased at 2m/min intervals
within 30 s after mice maintained their speed to 12m/min and
then to 14m/min for 900 s each.Mice were forced to run on a final
speed of 16m/min. The test was terminated individually, accord-
ing to the mouse’s endurance. A criterion of 10 shocks was set as
a termination marker for testing.
RESULTS
PHENOTYPE MEASUREMENTS
A high-content imaging assay was used to evaluate the cellu-
lar health status of the individual MEF lines after treatment
with 65 compounds. The design of the study allowed MEFs
from all 32 inbred mouse strains to be accommodated on a
single 384-well plate and treated with a single compound in 9-
point concentration-response curves with positive and negative
controls for each strain (Figure 1). The simultaneous culture,
treatment, and immunofluorescent staining of the 32 cell lines on
the same plate minimizes batch effects across strains that could
potentially confound the genetic analysis of the phenotypes. Since
a wide range of compounds with unknown toxic effects on MEFs
was tested, two incubation times were used; cells were treated for
24 and 72 h and three replicate plates were used for each time
point. Four endpoints were measured at both tested time points:
cell loss, mitochondrial function, apoptosis, and membrane per-
meability. For each strain, a comparison between vehicle only and
no vehicle wells did not show a significant difference in phenotype
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FIGURE 3 | Genomic region associated with rotenone cytotoxicity. (A)
GWA Manhattan plot for cell loss after 72 h of rotenone treatment. The region
with the highest -log p-value that was selected for further analysis is
indicated by the arrow. (B) Detail of the region in chromosome X annotated
with the candidate genes. (C) Haplotype structure of the inbred mouse
strains in the region. The black box indicates the 3-SNP haplotype with the
best SNPster association score, which includes the Cybb gene (chromosome
X 9,012,380–9,046,450).
values, suggesting that a 0.4%DMSO concentration did not cause
cellular toxicity. Based on the cell loss endpoint, 35 of the 65
compounds tested showed some cytotoxicity in the concentration
range tested, reaching the EC80 threshold. Across all endpoints, 38
compounds had a detectable cellular response, reaching either the
EC80 or EC120 thresholds (Data Sheet 5).
GENETIC ASSOCIATION ANALYSIS
The experimental design used in the study allowed each individ-
ual plate and associated replicates to be treated as a single unit
for the genetic analysis on each of the four endpoints and the two
time points. Although 38 compounds exhibited variable cellular
phenotype responses, not all of these responses were appropriate
for genetic analysis. To obtain a robust GWA, at least 25 or more
mouse strains were required to have at least three ECn values. This
ensures that the concentration range used was appropriate and
high enough to induce a cytotoxic response. The use of a com-
bined -log(p-value) from different ECn minimizes the effect of
curve slope variations in the final loci selection. Using this crite-
ria, a total of 28 compounds had genomic regions associated with
a phenotypic response as defined by having a combined mean -
log(p-value) of≥3.5 for at least one endpoint-time point pair. For
these compounds, a total of 196 genomic regions were identified,
with 538 unique RefSeq genes (547 total genes) mapped to 114 of
the regions. A list of the compound-time point pairs linked with
a putative QTL (-log p-value ≥3.5) as well as the QTGs for the
different endpoints is provided as supplementary material (Data
Sheet 4).
CANDIDATE GENE VALIDATION
To demonstrate that the approach can identify valid genetic mod-
ifiers, a candidate gene was selected for functional validation.
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FIGURE 4 | In vitro validation of Cybb in rotenone cytotoxicity. (A)
Concentration response of rotenone cytotoxicity following siRNA knockdown
of Cybb (n = 3 replicates at each concentration). Knockdown of the Cybb
gene shifts the concentration-response curve to the right. Dotted line
indicates the EC75. (B) Concentration response of rotenone cytotoxicity
following Cybb over-expression (n = 8 replicates at each concentration).
Over-expression of Cybb shifts the concentration-response curve to the left.
The dotted line shows the EC75. (C) Observed expression change in Cybb
with siRNA knockdown (n = 4 replicates), and (D) over-expression (n = 2
replicates). Data are expressed as means ± SE.
The cytotoxic response to rotenone exhibited robust phenotypic
changes that were variable across the different mouse strains. A
1.1Mb locus on Chromosome X (8.91–10.02Mb) was identi-
fied from genetic analysis, and this locus contained 10 candidate
genes. Among the 10 candidate genes, Cybb (aka Nox2) had a
strain distribution pattern that mirrored the haplotype structure
at the locus peak (Figure 3). Cybb has been traditionally thought
of as a component of the microbicidal oxidase system of phago-
cytes, but it is also expressed in other cell types such as neurons,
cardiomyocytes, skeletal muscle myocytes, hepatocytes, endothe-
lial cells, and hematopoietic stem cells (Bedard and Krause, 2007;
Anilkumar et al., 2008). Cybb is also expressed in MEFs (data not
shown).
It was hypothesized that changes in Cybb expression would
affect rotenone in vitro toxicity. Indeed, the knockdown of Cybb
in C57BL6/J MEFs using siRNA resulted in a shift of the rotenone
concentration-response curve to the right, EC75 shifted from
8.3μM (95% CI [4.9, 14.6]) to 38.3μM (95% CI [26.8, 62.2]).
Cybb over-expression in this same cell line, using a cDNA plasmid,
shifted the concentration response curve to the left, changing the
EC75 from 2.3μM (95% CI [1.4, 3.4]) to 0.8μM (95% CI [0.6,
1.1]) (Figures 4A–D).
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To evaluate the role of different Cybb haplotype groups in
rotenone toxicity in vivo, two mouse strains with different haplo-
types were tested for maintenance of aerobic capacity in the tread-
mill endurance test following repeated treatment with rotenone.
FVB/NJ mice (GGA haplotype group) showed a larger perfor-
mance deficit in the treadmill endurance test after rotenone
treatment compared to the BTBR T+ tf /J mice (ATG haplotype
group) (Figure 5). Only the FVB/NJ strain showed a signifi-
cant difference between rotenone- and control-treated mice (p =
0.02). On average, FVB/NJ vehicle-treated mice ran 1096m more
than rotenone-treated FVB/NJ mice.
PATHWAY ENRICHMENT AND NETWORK ANALYSIS
Due to the relatively low number of QTGs associated with each
endpoint, the candidate genes for all chemicals were combined
across all four endpoints prior to pathway enrichment analysis.
The enriched pathways consisted primarily of those relating to
G-protein signaling, cytoskeletal remodeling, and oxidative stress
(Table 1). Under the assumption that while the candidate genes
involved in the phenotypic differences may be distributed over a
wide range of pathways, theremay exist an underlying set of nodes
that are connected to multiple candidate genes and represent the
core of a network driving the adverse cellular responses. A net-
work analysis was performed and six over-connected nodes were
identified (Table 2).
DISCUSSION
Reports such as the NRC Toxicity Testing in the twenty-first
Century (National Research Council. Committee on Toxicity
Testing and Assessment of Environmental Agents, 2007) have sug-
gested performing toxicity testing of chemicals and drugs using
in vitro assays based on toxicity pathways. Identifying and char-
acterizing these pathways was listed in the NRC report as one
of the critical areas of knowledge development. In this study,
we describe an approach that combines in vitro screening with
genetic approaches for the experimental identification of genetic
loci modifying cellular responses to individual chemicals as well
as potential core nodes in putative toxicity pathways when applied
FIGURE 5 | In vivo validation of Cybb in rotenone toxicity using the
treadmill exhaustion test. Two inbred mouse strains were tested for
distance traveled during a 3.5 h time span in the stress treadmill test. The
mice treated with vehicle (n = 6 per strain) showed similar distances for
the two strains; however, FVB/NJ mice treated with rotenone (n = 6) had a
larger performance decrease than BTBR T+ tf /J mice (n = 6) ∗p < 0.05.
Data are expressed as means ± SE.
across large numbers of chemicals. The key development in this
screening method is the use of a well-characterized genetic model
that allows variable phenotype responses to be measured and
GWA analysis to identify potential QTG. The genetic intervals
defined using this approach are small enough to be able to identify
and test candidate genes for validation of association.
Recent advances in high-throughput screening technologies
have allowed researchers to test thousands of perturbations in
parallel in a cost-effective process. Specific application of high-
content imaging to in vitro toxicity testing maintains many
advantages as it permits multiplexed measurements of multi-
ple endpoints and the evaluation of subtle cytological changes
in response to chemical or drug treatment. High-content imag-
ing has been used to predict drug-induced liver injury using
cultured human hepatocellular carcinoma cells (HepG2), where
the observed cytotoxicity endpoints were highly concordant with
human hepatotoxicity (O’Brien et al., 2006).
In vitro toxicity studies for the purpose of genetic analysis
have relied mostly on the use of immortalized human cell lines.
Several groups have employed CEPH lymphoblastoid cell lines
to identify genomic regions and genes that are associated with
both pharmaco- and toxicogenetic responses (Huang et al., 2008;
Bleibel et al., 2009; Peters et al., 2009; Watson et al., 2011a,b;
Lock et al., 2012). The use of immortalized cell lines in these
studies provide considerable experimental convenience compared
Table 1 | Pathway enrichment analysis for combined set of candidate
genes.
Pathway Candidate genes in FDR
pathway/Total genes
G-protein signaling_Rap1A
regulation pathway
4/40 4.3E-02
G-protein signaling_Cross-talk
between Ras-family GTPases
3/23 6.8E-02
Cytoskeleton remodeling_RalA
regulation pathway
3/30 7.3E-02
G-protein signaling_G-Protein
alpha-q signaling cascades
3/34 7.3E-02
Oxidative stress_Role of ASK1
under oxidative stress
3/34 7.3E-02
G-protein signaling_RhoA
regulation pathway
3/34 7.3E-02
Table 2 | Over-connected nodes in network analysis of combined set
of candidate genes.
Node Protein function Number of interactions p-valuea
Myc Transcription factor 59 4.5E-06
Tnfrsf1a Receptor 9 3.5E-04
Cdk1 Kinase 18 4.0E-04
Prkacb Kinase 16 6.4E-04
Ppp2ca Phosphatase 9 2.0E-03
Inppl1 Phosphatase 4 5.1E-03
aAll over-connected nodes significant at FDR < 0.1.
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to primary cells, but significant factors cannot easily be controlled
in immortalized cell lines. These factors include a dysfunctional
apoptotic and cell cycle control mechanism, undefined or abnor-
mal genetic backgrounds acquired through mutations accumu-
lated with long-term tissue culture, and a lack of control of the
immortalization process (Marshak and Greenwalt, 2007; Welsh
et al., 2009). The use of human induced pluripotent stem cells
have been proposed as an alternative to toxicity testing, as these
cells can be expanded in culture and differentiated into the cell
types of interest; however, additional technical developments are
needed to make this possible (Scott et al., 2013).
The use of mouse cells in in vitro assays can overcome some of
the shortcomings associated with human cell-based systems. For
example, mouse models allow for easier access to primary cells
and experiments are more easily reproduced due to the genetic
stability of inbred strains. The existence of genetic information
for a large number of inbred mouse strains and the availabil-
ity of high-quality primary cells enable GWA studies based on
a cellular genetics approach. Inbred mouse strains also make
possible to perform QTG mapping; the strains are genetically
and phenotypically diverse and have a high number of recom-
binations, which improves mapping resolution (McClurg et al.,
2006). Mice have been used successfully in toxicogenetic studies
with results that were translatable to humans (Guo et al., 2006;
Harrill et al., 2009; Zhang et al., 2011) and are routinely used in
safety evaluation of drugs and other chemicals. Although toxic-
ity in rodents and humans is discordant in some cases (Shanks
et al., 2009), a relatively small number of inbred mouse strains
can be used to model the wide genetic and phenotypic vari-
ability found in human populations (Paigen and Eppig, 2000),
enabling high-throughput screens that capture a broad range of
response variance. Additionally, the capacity to identify genes
that modify the response to chemicals at a cellular level can still
provide insights into human toxicity mechanisms. Cytotoxicity
studies using cells derived from inbred mouse strains have been
performed (Watters et al., 2003), but not in a high-throughput
manner.
In our experimental set-up we proposed to broadly measure
aspects of cell health as we had selected a wide range of chemicals
to test in this generalized assay. We intended to show that even
with a general approach you could screen multiple compounds
and identify specific gene-drug associations, and importantly we
hypothesized that there would be some “common” toxicity path-
ways that are highlighted even when multiple compounds with
very different toxicity profiles were screened. We demonstrated
that it is possible to map QTL using high-content imaging data
from MEFs collected from an inbred mouse diversity panel and
treated with multiple chemicals and pharmaceutical compounds.
We identify candidate genes of interaction for multiple drugs,
and we selected one of these for more extensive validation. For
one of the treatments, a candidate gene, Cybb, was associated
with rotenone cytotoxicity. Cybb encodes for gp91phox, a sub-
unit of NADPH oxidase. Previous studies have demonstrated
that rotenone binds to gp91phox and activates NADPH oxidase
to induce superoxide production (Gao et al., 2003; Zhou et al.,
2012; Pal et al., 2014). The siRNA knockdown of Cybb was
consistent with an expected reduction in superoxide production
by rotenone exposure, leading to increased cell survival and a
right shift of the concentration-response curve. Conversely, the
over-expression of Cybb was consistent with increased superoxide
production, reduced cell survival, and a shift the concentration-
response curve to the left. These results are in concordance
with the neurotoxic effects of rotenone observed in gp91phox
knockout mice compared to wild-type animals (Gao et al.,
2003). From a broader perspective, the validation results demon-
strated that a cellular genetics approach can be used to identify
genes involved in the in vitro toxicological effects of specific
chemicals.
Translating the results from in vitro studies in embryo fibrob-
lasts to in vivo responses may not always be straightforward. In
our particular case, increasingly high concentrations of rotenone
led to cell death in vitro. If given at equivalent in vivo doses, a large
amount of cell death may result in organ failure or lethality, but
the relevance of these high concentration effects would be ques-
tionable. In order to examine potentially more relevant in vivo
effects of rotenone treatment, we hypothesized that repeated sub-
lethal doses of rotenone would result in reduced aerobic capacity
and lead to decreased performance in the treadmill endurance
test based on the role of gp91phox in cellular respiration. When
low dose of rotenone was administered daily over the course of
14 days, the FVB/NJ mouse strain showed a greater performance
deficit after rotenone treatment compared to the BTBR T+ tf /J
mouse strain, as we predicted from cell-based studies. Although
there are no Cybb non-synonymous SNPs among the selected
set of strains, multiple SNPs in the coding and 3′-UTR regions
follow the same haplotype distribution pattern as the one that
was associated with rotenone response, which suggests that these
SNPs could potentially have an effect on the amount of protein.
Based on the Cybb expression profile from the inbred strains in
several different tissues (for example, the strain expression pro-
file of Cybb in adipose tissue and the EC50 response of MEFs
to rotenone is highly correlated with a p-value < 8.95 × 10−5),
we hypothesize that the differential expression of Cybb between
strains is the likely cause of the differential response to rotenone.
These studies demonstrate that a cell-based QTL mapping result
could lead to identification of genetic variants that are relevant to
whole-organism toxicological responses.
To evaluate the candidate genes across multiple chemicals,
pathway enrichment analysis was performed on the candidate
genes combined across endpoints and treatments. The major-
ity of candidate genes were distributed over a range of pathways
resulting in a limited number that were statistically enriched. The
wide distribution may be due to a number of factors includ-
ing the false positive genes present in the list, the diversity
of pathways involved in the integrated cellular responses, or
the diversity in toxicological modes-of-action across the chem-
icals evaluated. In each case, spreading the candidate genes
across a range of pathways would diminish the statistical enrich-
ment of any one putative toxicity pathway. Those pathways
that were enriched could be considered toxicity pathways and
consisted primarily of those relating to G-protein signaling,
cytoskeletal remodeling, and oxidative stress. Of those enriched,
a previous study has linked inhibition of RhoA signaling to
adriamycin-induced cardiomyopathy (Wang et al., 2011). Other
Frontiers in Genetics | Toxicogenomics August 2014 | Volume 5 | Article 272 | 10
Suzuki et al. High-throughput screening identifies gene-drug interactions
studies have linked ASK1 signaling to acetaminophen-induced
apoptosis in the liver (Niso-Santano et al., 2010), angiotensin
II-induced cardiac injury (Nako et al., 2012), 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) toxicity (Lee et al., 2012),
troglitizone-induced hepatocellular injury (Lim et al., 2008), and
other adverse responses.
Due to the low number of significantly enriched pathways, net-
work analysis was performed to identify over-connected nodes
among the candidate genes. The rationale for performing this
type of analysis was that even though the candidate genes may be
spread across a range of canonical signaling pathways, there may
exist a set of core nodes connecting the genes that represent crit-
ical junctions in toxicity networks. Among the nodes identified,
Myc was highly over-connected among the candidate genes. Myc
is a well-known transcription factor with a global influence in the
cell transcriptome, and it plays key roles in cell growth and apop-
tosis (Dang et al., 2006). Likewise, Tnfrsf1a is a cellular receptor
that plays a role in cell growth, death, and stress response (Chen
and Goeddel, 2002). Cdk1 is a catalytic subunit of the M-phase
promoting factor (MPF) and is essential for G1/S andG2/Mphase
transitions of the cell cycle (Rhind and Russell, 2012). Prkacb is a
cAMP-dependent protein kinase that has diverse effects on cellu-
lar function (Daniel et al., 1998). Some of these functions include
regulation of proto-oncogenes (Wu et al., 2002), regulating cel-
lular localization of signaling proteins and receptors (Higuchi
et al., 2003), and altering stability of nuclear receptors (Yum et al.,
2009). Ppp2ca is one of the four major Ser/Thr phosphatases
and it plays a key role in many critical cellular processes through
the dephosphorylation of signaling molecules such as Akt, p53,
Myc, and β-catenin (Seshacharyulu et al., 2013). Finally, Inppl1
(aka Ship2) is involved in the regulation of insulin function
(Vinciguerra and Foti, 2006) and also plays a role in the regu-
lation of epidermal growth factor receptor turnover (Zwaenepoel
et al., 2010), and actin remodeling (Venkatareddy et al., 2011).
In each case, the over-connected genes are associated with critical
cellular functions that when excessively perturbed will likely lead
to adverse effects.
In summary, we demonstrated that genetically characterized
primary cell lines from multiple inbred mouse strains can be uti-
lized within in vitro toxicology assays. Inbred mouse strain panels
are widely used to detect the genetic contributions to complex dis-
eases and other phenotypes; here, we show the use of this valuable
model population in a flexible and scalable in vitro toxicogenomic
pipeline. The variable cellular responses among the tested strains
enables genetic association analysis and provide relatively small
loci, facilitating the path to downstream QTG validation studies.
The inbred mouse strains provide a unique renewable resource
for in vitro screens as well as allow for downstream in vivo val-
idation studies. Through follow-up studies, we have shown the
utility of a screen using these cells to uncover a validated target
in the in vitro toxicity of a chemical. Importantly, the findings
from the screen were also shown to be translatable to a differ-
ential response in the whole animal. On a broader scale, the use
of the approach enables a large number of compounds to be
efficiently screened for the identification of putative toxicity path-
ways and core nodes in toxicity networks. Of note, this approach
has also been shown in our lab to be applicable for other cell types
(i.e., splenocytes), which could provide an innovative means for
assessing specific toxicities for a particular class of compounds
(Frick et al., 2013).
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